Japan Pharmaceutical Logistics Market Assessment, By Type [Cold Chain Logistics, Non-Cold Chain Logistics], By Procedure [Picking, Storage, Retrieval Systems, Handling Systems], By Component [Storage, Transportation, Monitoring Component], By Application [Chemical Pharma, Biopharma, Specialized Pharma], By Operation [Seaways, Roadways, Railways, Airways, Storage and Services], By Region, Opportunities and Forecast, FY2019-FY2033F

Japan pharmaceutical logistics market is projected to witness a CAGR of 5.93% during the forecast period FY2026-FY2033, growing from USD 5.32 million in FY2025 to USD 8.43 million in FY2033 due to growth in pharmaceutical demand, increasing complexity of pharmaceutical supply chains, and stringent regulatory requirements. Japan pharmaceutical logistics market stands at the intersection of precision, regulation, and innovation. As the country faces a rising demand for high-value therapeutics, including biopharma, specialty drugs, and personalized medicine, the pressure to ensure safe, compliant, and timely delivery is more critical than ever. With Japan’s aging population and strict regulatory requirements, logistics partners are not just expected to deliver, they are also expected to preserve therapeutic integrity down to the last kilometer.

Report Attributes	Details
Base Year	FY2025
Forecast Period	FY2026-FY2033F
Historical Period	FY2019-FY2024
Projected Growth Rate	CAGR of 5.93% between FY2026 and FY2033
Revenue Forecast in FY2033	USD 5.93 million

Post-COVID, the country has accelerated investments in cold chain infrastructure, automation, and real-time monitoring technologies, transforming logistics from a back-end cost center into a front-line enabler of healthcare access. Temperature excursions, transit delays, and manual errors are now unacceptable in an industry where 2 degrees Celsius fluctuation can render a shipment worthless.

For instance, in September 2023, Takeda Pharmaceutical partnered with Mitsubishi Logistics and JR Freight to pilot a temperature-controlled rail transport solution for pharmaceuticals. This initiative marked a significant shift from conventional road methods, achieving a 60% reduction in CO₂ emissions while maintaining strict GDP-compliant temperature control and mitigating vibration risks, representing the first rail-based pharmaceutical logistics system of its kind in Japan.

Surge in Cold Chain Logistics for Biopharma and Vaccines Fuels Market Growth

Japan’s biopharmaceutical sector has expanded rapidly, from monoclonal antibodies to mRNA-based treatments, and these drugs require stable cold chain environments to maintain efficacy. This has triggered a nationwide upgrade in temperature-controlled logistics.

In November 2023, Bushu Pharmaceuticals Ltd. opened the Soka Packaging Center, its 5th base in Japan, inside Prologis Park Soka. This state-of-the-art facility, featuring advanced ecological and safety technologies, offers extensive storage and packaging services for biological and regenerative medical products. The center’s capabilities include storing 1,671 pallets at 2−8 degrees Celsius and providing easy access to refrigerated storage from truck berths. This expansion helps Bushu Pharma meet the growing demand for pharmaceutical medicines by ensuring optimal cold storage supply chain operations, contributing to Japan's cold chain logistics market's growth through enhanced efficiency, technology adoption, and ecological sustainability.

In March 2024, Yusen Logistics Co., Ltd. received CEIV Pharma recertification for its Narita International Airport facility as of March 13, 2024. The Narita Healthcare Terminal, opened in 2023, is now certified for pharmaceutical handling and operates in full compliance with Good Distribution Practice (GDP). The facility features advanced temperature controls, supporting pharmaceutical cargo at -20 degrees Celsius, +5 degrees Celsius, and +20 degrees Celsius, to accommodate a wide range of temperature-sensitive medicines.

Hospital-Focused Distribution and Urban Last-Mile Innovation to Shape the Market

Urban healthcare facilities in Japan, especially in Tokyo and Osaka, require strict delivery SLAs for specialty drugs, blood products, and urgent-care items. To meet these demands, logistics companies are innovating last-mile solutions suited for dense urban geographies. Urban-centric innovation in healthcare logistics is becoming a key differentiator in provider partnerships and SLA bidding.
For example, in June 2024, CONCOR (Container Corporation of India Ltd.) and Innovation Thru Energy (ITE), Japan, teamed up to introduce ice battery technology in containers for temperature-sensitive cargo, eliminating the need for diesel generators and maintaining freshness for up to 72 hours. This environmentally friendly solution reduces CO2 emissions by 70-80% and enhances the efficiency of cold chain logistics.

Dominance of Specialized Pharma in Logistics Demand

In Japan, specialized pharmaceuticals, including oncology drugs, orphan disease treatments, biosimilars, and advanced therapy medicinal products (ATMPs) such as cell and gene therapies, are rapidly becoming the most logistics-intensive and commercially valuable segment of pharmaceutical logistics. As Japan’s aging population drives a rise in complex, chronic, and rare conditions, the healthcare system is moving toward precision therapies that require strict temperature controls, tighter delivery windows, and near-zero error tolerance. These products often carry short shelf lives, high unit value, and sensitivity to vibration or light, making them especially dependent on specialized logistics networks.

In August 2023, Mitsubishi Logistics Corporation responded to this trend by enhancing its biopharma transport suite with a cloud-integrated logistics visibility platform. The system enables pharmaceutical clients to monitor real-time shipment conditions across storage hubs, roadways, and hospital endpoints, with support for 2 degrees Celsius –8 degrees Celsius, −20 degrees Celsius, and ultra-cold chain below −70 degrees Celsius specifications.

Meanwhile, in February 2025, Essential Pharma Limited (“Essential Pharma”) and Clinigen Group plc (“Clinigen”) announced an expansion of their JAPAC collaboration to enhance patient access to four therapies in Japan and Korea and strengthen their joint market presence in the region. The expanded partnership includes new market authorisation transfers and exclusive distribution agreements. Building on their 2024 agreement for IOPIDINE (apraclonidine) in Korea, the companies have now extended this arrangement to Japan.

Download Free Sample Report

Impact of U.S. Tariffs on Japan Pharmaceutical Logistics Market

• S. tariffs on pharmaceutical ingredients and packaging supplies—especially those sourced from China and rerouted via U.S. suppliers—have caused upstream pricing volatility. Japanese pharmaceutical manufacturers have had to adapt by sourcing APIs and sterile packaging from alternate regions (e.g., India, Europe), adding pressure on logistics timelines and import scheduling.
• To avoid tariff-induced bottlenecks, Japanese logistics firms have re-routed critical pharma shipments away from U.S. transshipment hubs, especially for high-value biopharmaceuticals. This shift has led to increased reliance on regional air cargo routes (via Incheon, Singapore, or Dubai), changing the way 3PLs and 4PLs structure cold chain handoffs and storage.
• Higher import costs and trade friction have incentivized Japanese pharma companies to localize more of their logistics infrastructure — investing in domestic GDP-certified cold storage, regional fulfillment hubs, and automated handling systems. This is especially true for firms distributing to hospitals, where lead time and compliance are critical.

Report Scope

“Japan Pharmaceutical Logistics Market Assessment, Opportunities and Forecast, FY2019-FY2033”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of Japan pharmaceutical logistics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecasts between 2026 and 2033. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Segments Covered	Type, Procedure, Component, Application, Operation
Regions Covered	North, Central, South
Key Companies Profiled	A.P. MØLLER - MÆRSK A/S, CEVA Logistics SA, Nippon Express Co., Ltd., Logisteed Ltd., Kintetsu World Express, Inc., Yamato Transport Co., Ltd., Sagawa Express Co., Ltd., Yusen Logistics Co., Ltd., Mitsubishi Logistics Corporation, DHL International GmbH
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, the Japan pharmaceutical logistics market has been segmented into the following categories: 

• By Type
  • Cold Chain Logistics
  • Non-Cold Chain Logistics
• By Procedure
  • Picking
  • Storage
  • Retrieval Systems
  • Handling Systems
• By Component
  • Storage
  • Transportation
  • Monitoring Component
• By Application
  • Chemical Pharma
  • Biopharma
  • Specialized Pharma
• By Operation
  • Seaways
  • Roadways
  • Railways
  • Airways
  • Storage and Services
• By Region
  • North
  • Central
  • South

Key Players Landscape and Outlook

Japan pharmaceutical logistics market is led by a mix of domestic giants and global specialists. Companies offer end-to-end cold chain, GDP-certified storage, and hospital delivery across all prefectures. Whereas, Yusen Logistics and Sagawa Express are rapidly digitizing operations with IoT and temperature-mapping solutions tailored to Japanese geography. International players provide value in air-sea integration and biosecure customs clearance. Logisteed and Kintetsu World Express are developing niche services in research sample handling and biopharma packaging. As regulatory pressures increase, service providers are competing on audit-readiness, SLA precision, and pharma-centric innovation, not just speed or cost.

For instance, in February 2025, Logisteed, Ltd. opened its new Kansai Logistics Center (Kyoto Kameoka) in Kameoka City, Kyoto Prefecture. Operated by Logisteed Chemical, Ltd., the state-of-the-art facility features seven warehouses and specializes in the handling of hazardous materials. Strategically located in a major industrial area with excellent transport links, the center ensures regulatory compliance for the storage of hazardous goods across sectors, including chemicals, cosmetics, pharmaceuticals, and lithium batteries, further strengthening customer supply chains in the pharmaceutical industry.

Key Players Operating in the Japan Pharmaceutical Logistics Market are:

• P. MØLLER - MÆRSK A/S
• CEVA Logistics SA
• Nippon Express Co., Ltd.
• Logisteed Ltd.
• Kintetsu World Express, Inc.
• Yamato Transport Co., Ltd.
• Sagawa Express Co., Ltd.
• Yusen Logistics Co., Ltd.
• Mitsubishi Logistics Corporation
• DHL International GmbH

If you can't find what you're searching for or have any custom requirements for the Japan pharmaceutical logistics market, you may approach our team at info@marketsandata.com